#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hormone-dependent prostate cancer Angiosarcoma metastatic Pyoderma gangrenosum Hereditary ataxia Mitochondrial myopathy Nephrotic syndrome Mitochondrial DNA depletion Craniopharyngioma Cutaneous T-cell lymphoma stage II Monogenic diabetes Homocystinuria Nasopharyngeal cancer Angiosarcoma non-metastatic Primary adrenal insufficiency Cluster headache More trials…

    Learn about Rare Diseases

    KBG syndrome – Diagnostics Methylmalonic acidaemia – Diagnostics Ornithine transcarbamoylase deficiency – Basic Information Advanced systemic mastocytosis – Diagnostics Medulloblastoma Waldenstrom’s macroglobulinaemia refractory Rhabdoid tumour – Treatment Hereditary ataxia – Basic Information Hepatoblastoma – Trials in Disease Castleman’s disease – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Foscarnet [99MTC]PSMA I&S Methylprednisolone Mercaptopurine NORETHISTERONE ACETATE Tolvaptan SUMATRIPTAN Valoctocogene Roxaparvovec Ficlatuzumab Sonidegib L-METHIONINE SIPAVIBART Eribulin Mesylate Odevixibat Anidulafungin Gallium (68Ga) Chloride Human Coagulation Factor Ix Linerixibat Cd19-Car_Lenti_Allo Tulmimetostat More therapies…

    Learn about Your Condition

    Uveitis Hypophosphatasia Androgenetic alopecia Eye inflammation Haemofiltration Mesothelioma Oropharyngeal cancer recurrent Bile duct cancer MELAS syndrome Bacterial prostatitis Laryngeal cancer stage III Hepatic encephalopathy Prostate cancer Synovial sarcoma metastatic Arginase deficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on Botulinum Toxin Type A and Sodium Chloride for Patients with Treatment-Resistant Chronic Cluster Headache

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cluster headache
    Investigated Drugs:
    • Botulinum Toxin Type A
    • Sodium Chloride
    Germany Norway

  • Study of Chemotherapy with or without FUDR/Dexamethasone for Patients with Inoperable Liver Bile Duct Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Floxuridine
    The Netherlands

  • Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Retroperitoneal cancer
    • Endometrial cancer
    • Fallopian tube cancer
    Investigated Drugs:
    • Bevacizumab
    • Olaparib
    Spain

  • Study on Adding Atezolizumab and WT1/DC Vaccine to Standard Treatment for Patients with Epithelioid Malignant Pleural Mesothelioma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Wt1 Lamp Mrna Dc
    • Atezolizumab
    Belgium

  • Comparison of ruxolitinib versus hydroxycarbamide or interferon alfa as first treatment for high-risk polycythemia vera patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Polycythaemia vera
    Investigated Drugs:
    • Hydroxycarbamide
    • Peginterferon Alfa-2A
    • Ruxolitinib
    France

  • Study on Alzheimer’s Disease Using Flortaucipir (18F) for Early Diagnosis in At-Risk Patients

    Recruiting

    2 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Flortaucipir (18F)
    France
Previous Page
1 … 409 410 411 412 413 … 1,651
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!